MTOR and central nervous system neoplasm: Here we have used a proprietary AI-based platform to identify a novel combination of the multi-RTK inhibitor vandetanib alongside the mTOR inhibitor everolimus, taking advantage of the abilities of the latter drug to inhibit both mTOR and the ABC efflux transporter pumps, which has previously limited clinical utility of the former compound against CNS tumors.